RiaSTAP

Product Specs	RiaSTAP
Manufacturer Name	CSL Behring
Indications	For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia
Contraindications	Anaphylactic or severe reactions to RiaSTAP or its components. Not indicated for dysfibrinogenemia
Viral Safety Process	FDA-licensed serological assays, nucleic acid testing
Product Half-Life	Adults 82.3 ± 20.0 hours Children 69.9 ± 8.5 hours
Manufacturing Method	Cryoprecipitate into a glycine precipitate, which is then further purified by multiple precipitation/adsorption steps
Storage Requirements/Shelf Life	Store at temperatures of 2-8°C (36-46°F) Stable for up to 60 months indicated by expiration date on the label. Keep in its original carton to protect from light. Do not freeze.
Nominal Vial Size & Diluent Volume	900 mg to 1300 mg/50 mL